NASDAQ:MESO 3 October 2025 - 12 January 2026

Mesoblast shares closed at $17.02 on Oct. 2, up 4.6% after the FDA-approved Ryoncil won permanent CMS reimbursement via a new J-code. The company confirmed its cell therapies are made from U.S. donors and not subject to tariffs. Wall Street consensus is “Buy” with a $24 average price target. Hedge funds have increased stakes, but overall institutional ownership remains low.